

PF-0484 US

What is claimed is:

A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment of SEQ ID/NO:1.

5

2. A substantially purified variant having at least 90% amino acid sequence identity to the sequence of claim 1.

MioB

- 3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
- 4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
- 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
- 6. An isolated and purified polynucleotide which is complementary to the polynucleotide of claim 3.

7. An isolated and purified polynucleotide comprising the polynucleotide sequence of SEQ ID NO:2 or a fragment of SEQ ID NO:2.

8. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 7.

25

9. An isolated and purified polynucleotide having a sequence complementary to the polynucleotide of claim 7.

30 claim 3.

O. An expression vector containing at least a fragment of the polynucleotide of



- 11. A host cell containing the expression vector of claim 10.
- 12. A method for producing a polypeptide comprising a sequence of SEQ ID NO:1 or a fragment of SEQ ID NO:1, the method comprising the steps of:
 - (a) culturing the host cell of claim 11 under conditions suitable for the expression of the polypeptide; and
 - (b) recovering the polypeptide from the host cell culture.
- 13. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
 - 14. A purified antibody which specifically binds to the polypeptide of claim 1.
 - 15. A purified agonist of the polypeptide of claim 1.
 - 16. A purified antagonist of the polypeptide of claim 1.
 - 17. A method for treating or preventing a neurological disorder, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13
 - 18. A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13
 - 19. A method for treating or preventing a cell proliferative disorder, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13.
 - 20. A method for detecting a polynucleotide encoding a polypeptide comprising

30

25

5

10

PF-0484 US

the amino acid sequence of SEQ ID NO:1 in a biological sample containing nucleic acids, the method comprising the steps of:

- (a) hybridizing the polynucleotide of claim 6 to at least one of the nucleic acids of the biological sample, thereby forming a hybridization complex; and
- (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding the polypeptide in the biological sample.
- 21. The method of claim 20 wherein the nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.